# Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

> **NCT02330406** · PHASE4 · COMPLETED · sponsor: **Institute for Clinical Effectiveness, Japan** · enrollment: 353 (actual)

## Conditions studied

- Dipeptidyl-Peptidase 4 Inhibitors
- LDL Cholesterol
- Glycosylated Hemoglobin
- Diabetes Mellitus
- Coronary Disease

## Interventions

- **DRUG:** Anagliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT02330406
- **Lead sponsor:** Institute for Clinical Effectiveness, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-01
- **Final completion:** 2019-03
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02330406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02330406, "Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02330406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*